Company profile for Nanoscope Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. We utilize ambient light-sensitive molecule to re-senitize the retina toward low light level. Our light-assisted gene therapy is highly targeted to geographic atrophies without perturbing t...
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. We utilize ambient light-sensitive molecule to re-senitize the retina toward low light level. Our light-assisted gene therapy is highly targeted to geographic atrophies without perturbing the intact retina circuitry. Our team is highly experienced in Ophthalmology product development and clinical translation of innovative research.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1312 Brown Trail Suite A Bedford, TX 76022
Telephone
Telephone
(817) 719-2692
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/nanoscope-therapeutics-featured-in-multiple-presentations-at-advanced-therapies-usa-2025-302616472.html

PR NEWSWIRE
17 Nov 2025

https://www.prnewswire.com/news-releases/nanoscope-therapeutics-reports-five-year-safety-results-from-phase-12a-follow-up-study-of-mco-010-optogenetic-therapy-in-retinitis-pigmentosa-302603355.html

PR NEWSWIRE
04 Nov 2025

https://www.prnewswire.com/news-releases/nanoscope-strengthens-global-regulatory-pathways-for-mco-010-with-fda-rmat-and-five-ema-orphan-designations-302543344.html

PR NEWSWIRE
02 Sep 2025

https://www.prnewswire.com/news-releases/nanoscope-announces-groundbreaking-3-year-remain-trial-data-for-patients-with-retinitis-pigmentosa-at-2025-euretina-congress-and-retina-society-annual-scientific-meeting-302538281.html

PR NEWSWIRE
26 Aug 2025

https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-publication-of-starlight-phase-2-study-evaluating-mco-010-gene-agnostic-therapy-in-patients-with-stargardt-disease-302530171.html

PR NEWSWIRE
14 Aug 2025

https://www.prnewswire.com/news-releases/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting-302514594.html

PR NEWSWIRE
28 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty